---
url: https://www.servicesaustralia.gov.au/leukaemia-acute-myeloid-leukaemia
title: Leukaemia - acute myeloid leukaemia - Health professionals - Services AustraliaServices AustraliaServices Australia
scrapedAt: 2026-02-20T21:41:00.201Z
source: servicesaustralia.gov.au
---
# Leukaemia - acute myeloid leukaemia

The PBS subsidises azacitidine, daunorubicin+cytarabine, decitabine+cedazuridine and midostaurin for patients with acute myeloid leukaemia (AML).

## on this page

-   [Patient eligibility](#a1)
-   [Section 100 arrangements - Highly Specialised Drugs](#a2)
-   [Section 100 - Efficient Funding of Chemotherapy](#a3)
-   [Authority applications](#a4)
-   [More information](#a5)

Please note: You’ll get an immediate assessment when you request [PBS authorities online](/apply-for-pbs-authority?context=20#accordion1).

## Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with azacitidine (injection), daunorubicin+cytarabine and midostaurin under the _National Health Act 1953_, section 100 for patients with AML.

The PBS subsidises treatment with azacitidine (tablet) and decitabine+cedazuridine under the _National Health Act_, section 85 for patients with AML.

Patients must be eligible for the [PBS](/pharmaceutical-benefits-scheme) and meet the relevant restriction criteria.

The [Schedule of Pharmaceutical Benefits](http://www.pbs.gov.au/pbs/home) on the PBS website outlines the restrictions for prescribing azacitidine, daunorubicin+cytarabine, decitabine+cedazuridine and midostaurin.

## Section 100 arrangements - Highly Specialised Drugs

### azacitidine (injection) and midostaurin

These items are only PBS-subsidised for non-admitted patients, day admitted patients or patients on discharge who are attending either:

-   an approved private hospital
-   a public hospital.

These items aren’t PBS-subsidised for hospital in-patients. You must include the hospital name and provider number on the authority application form.

## Section 100 - Efficient Funding of Chemotherapy

### daunorubicin+cytarabine

This item is only PBS-subsidised for non-admitted patients, day admitted patients or patients on discharge who are attending either:

-   an approved private hospital
-   a public participating hospital.

This item isn’t PBS-subsidised for hospital in-patients.

## Authority applications

### azacitidine (injection)

#### Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised azacitidine injection to treat AML can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

#### Applying for continuing treatment

Continuing PBS-subsidised treatment with azacitidine injection is Authority Required (Streamlined). You don’t need authority approval from us for the listed quantities and repeats.

### azacitidine (tablet)

#### Applying for initial treatment following intensive induction chemotherapy

Applications for initial authority approval to prescribe PBS-subsidised azacitidine (tablet) to treat AML can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

#### Applying for continuing treatment following intensive induction chemotherapy

Applications for continuing authority approval to prescribe PBS-subsidised azacitidine (tablet) to treat AML can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

#### Applying for continuing treatment - dose escalation therapy

Applications for continuing authority approval to prescribe PBS-subsidised azacitidine (tablet) as dose escalation therapy to treat AML can be made in:

-   real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   writing and use [HPOS Form upload](/upload-forms-hpos?context=20)
-   writing and mail to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [acute myeloid leukaemia - oral azacitidine - dose escalation therapy continuing authority application form](/pb355?context=20)
-   relevant attachments.

### decitabine+cedazuridine

#### Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised decitabine+cedazuridine to treat AML can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS authority approvals enquiry line](/health-professionals-contact-information?context=20#pbsauthority).

#### Applying for continuing treatment

Continuing PBS-subsidised treatment with decitabine+cedazuridine is Authority Required (Streamlined). You don’t need authority approval from us for the listed quantities and repeats.

### daunorubicin+cytarabine

#### Applying for induction treatment

Applications for induction authority approval to prescribe PBS-subsidised daunorubicin+cytarabine to treat AML can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

#### Applying for consolidation treatment

Applications for consolidation authority approval to prescribe PBS-subsidised daunorubicin+cytarabine to treat AML can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

### midostaurin

#### Applying for induction and consolidation treatment

Applications for induction and consolidation authority approval to prescribe PBS-subsidised midostaurin to treat AML can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

#### Applying for initial maintenance treatment

Applications for initial maintenance authority approval to prescribe PBS-subsidised midostaurin to treat AML can be made in:

-   real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   writing and use [HPOS Form upload](/upload-forms-hpos?context=20)
-   writing and mail to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [acute myeloid leukaemia - midostaurin - initial maintenance authority application form](/pb253?context=20)
-   relevant attachments.

#### Applying for continuing maintenance treatment

Applications for continuing maintenance authority approval to prescribe PBS-subsidised midostaurin to treat AML can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

## More information

Call the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs) for more information.
